Meng Xiaojuan, Gao Yajie, Qi Hang, Ding Yongyan, Sun Yaqing
Department of Psychiatry, The Eighth Hospital of Shijiazhuang, Hebei, China.
Department of Outpatient, The Eighth Hospital of Shijiazhuang, Hebei, China.
Clin Psychopharmacol Neurosci. 2022 Aug 31;20(3):560-566. doi: 10.9758/cpn.2022.20.3.560.
PS128 is a novel psycho biotic strain, it has been reported to play an important role in neuropsychiatric disorders. This study investigated the clinical effect of PS128 supplementation on patients with anxiety.
A total of 200 patients with anxiety were recruited, and divided into two groups (n = 100/group). The control group received oral treatment with citalopram, and the PS128 group received PS128 capsules based on citalopram treatment. Hamilton Anxiety Scale (HAMA) and Self-Rating Anxiety Scale (SAS) were used to evaluate the anxiety levels. After 2 months of continuous administration, clinical efficacy was evaluated according to HAMA score.
There was no significant difference in HAMA and SAS scores between the two groups before treatment. With the treatment prolonged, the HAMA and SAS score decreased gradually in both control and PS128 groups, and the decrease rate of PS128 group was significantly greater than that of the control group. The clinical effective rates of PS128 group were higher than those in the control group, high levels of clinical cure rate were also detected in the PS128 group. Compared with the control group (22%), the incidence of adverse reactions was significantly reduced for patients in the PS128 group (4%).
The treatment effect of citalopram combined with PS128 against anxiety is satisfactory clinically. It can greatly improve the anxiety symptoms of patients, increase the cure rate, reduce adverse reactions.
PS128是一种新型的精神益生菌株，据报道在神经精神疾病中发挥重要作用。本研究调查了补充PS128对焦虑症患者的临床效果。
共招募200例焦虑症患者，分为两组（每组n = 100）。对照组接受口服西酞普兰治疗，PS128组在西酞普兰治疗的基础上接受PS128胶囊治疗。采用汉密尔顿焦虑量表（HAMA）和自评焦虑量表（SAS）评估焦虑水平。连续给药2个月后，根据HAMA评分评估临床疗效。
治疗前两组HAMA和SAS评分无显著差异。随着治疗时间延长，对照组和PS128组的HAMA和SAS评分均逐渐降低，且PS128组的降低率显著大于对照组。PS128组的临床有效率高于对照组，PS128组的临床治愈率也较高。与对照组（22%）相比，PS128组患者的不良反应发生率显著降低（4%）。
西酞普兰联合PS128治疗焦虑症的临床效果令人满意。它可以显著改善患者的焦虑症状，提高治愈率，减少不良反应。
